Aficamten delivers on both symptoms AND exercise capacity in obstructive HCM. Two primary endpoints hit. 🧵 📋 KCCQ-CSS (symptoms): LSM difference vs placebo: 3.0 points (p=0.021) Separation emerges early, sustained through 72 weeks. Effect disappears during washout — confirming on-target mechanism. 🏃 pVO₂ (exercise capacity): LSM difference at Week 36: 0.67 mL/kg/min (p=0.003) Placebo essentially flat. Aficamten meaningfully improves peak aerobic capacity. Both endpoints are what patients feel and what limits their lives. Hitting both with a well-tolerated oral cardiac myosin inhibitor is a meaningful step for obstructive HCM. #HCM #Aficamten #ObstructiveHCM #CardiacMyosinInhibitor #Cardiology

Just read a great analysis from the SEQUOIA-HCM trial looking at the efficacy of aficamten, a selective cardiac myosin inhibitor, across different geographic regions 🌍. Despite clear differences in baseline characteristics between Europe, North America, and China, the dosing, safety, and treatment effects of aficamten were remarkably consistent everywhere. Improvements in exercise capacity, LVOT gradients, and symptoms were seen independent of region — which is a big deal when we think about how diverse HCM populations really are. For me, it’s another reminder of how exciting this phase is in HCM: moving from purely symptomatic management to targeted, disease-specific therapies 🚀 Still learning, still exploring new ground… and honestly, loving it 🤓 #HCM #ObstructiveHCM #Aficamten #CardiacMyosinInhibitors #Cardiology #ClinicalTrials #TranslationalMedicine #PrecisionMedicine #Cardiomyopathy #ESC #Research #LearningEveryDay doi.org/10.1093/eschf/xvag02…

🫀👵👴 Septal reduction therapy in elderly patients with obstructive HCM: ASA or myectomy? A new study from a high-volume HCM center compared alcohol septal ablation (ASA) and transaortic septal myectomy in patients ≥75 years with obstructive hypertrophic cardiomyopathy. Using propensity-matched cohorts (95 vs 95 patients), the authors looked at survival, LVOT gradients, and need for reintervention. 🔍 Key findings: 👉 Procedural risk was low for both strategies (operative mortality 0% with ASA vs 1% with myectomy) 👉 Complete heart block requiring pacemaker was significantly more frequent after ASA (23% vs 10%) 👉 Survival was similar between groups and comparable to an age- and sex-matched general population 👉 LVOT gradient reduction was more complete with myectomy, both early and at late follow-up 👉 Reintervention was more common after ASA (trend toward higher rates) 💡 Take-home message: In elderly patients with obstructive HCM, both ASA and surgical myectomy are safe and effective when performed in experienced centers. Myectomy provides more complete relief of obstruction, while overall early and long-term outcomes remain largely similar, highlighting the importance of individualized, multidisciplinary decision-making. #HypertrophicCardiomyopathy #HCM #ObstructiveHCM #SeptalMyectomy #AlcoholSeptalAblation #StructuralHeartDisease #ElderlyPatients #CardiacSurgery #InterventionalCardiology #PrecisionMedicine #HeartTeam 🫀🩺📊✨ doi.org/10.1016/j.jacadv.202…

🫀✨ Mavacamten in real life: the Italian experience This large real-world study describes the baseline profile of patients with obstructive HCM treated with mavacamten in the Italian Early Access Program. 🇮🇹 Who were the patients? • 337 patients from 54 Italian centres • Mean age: 61 years • 53% male • Most in NYHA class II–III • More advanced disease than clinical trials 🔍 Compared with EXPLORER-HCM trial: • Older patients • Lower LVEF • Larger left atrium • Higher biomarkers (NT-proBNP, troponin) ➡️ Real life = sicker and more complex patients ⚡ Septal reduction therapy (SRT): • Only 22% eligible for surgery • Most symptomatic patients were not candidates for SRT • Yet many still had significant LVOT obstruction 💊 Why mavacamten matters: • Offers a new option for patients: – Symptomatic – Not responding to standard drugs – Not eligible for surgery • Should be seen as complementary, not alternative, to SRT 📌 Take-home: Real-world oHCM patients are older and more advanced than trial populations. Mavacamten fills a major therapeutic gap — especially for those who have no surgical option. #HCM #ObstructiveHCM #Mavacamten #MyosinInhibitor #Cardiomyopathy #HeartFailure #RealWorldData #Cardiology 🫀💊📊 doi.org/10.1016/j.ijcard.202…

*Only 11 weeks* until International @HCMSummit 8. Don't miss #PremShekar's talk: "Operating on #ObstructiveHCM with Mild Septal Hypertrophy: Expanding the #Myectomy Spectrum." Secure your seat today at hcmsummit.org/tickets. #cardiotwitter #cardioed #hypertrophiccardiomyopathy

Continuing our #HeartFailure in #ObstructiveHCM discussion, @AWangDukeU presents, "What is the Evidence for #CardiacRemodeling w/ #MyosinInhibitors And Is It Different Than with #SeptalReduction Therapies?" Register at hcmsummit.org. #CardioTwitter #CardioEd #HCMSummit8

Next on the agenda for #HeartFailure in #ObstructiveHCM at @HCMSummit (Boston | Oct 25-27) is my event co-director @MartinMaronMD with his talk on what to expect from new #CardiacMyosinInhibitors. Learn more at hcmsummit.org. #CardioTwitter #CardioEd #HCMSummit8

My co-director @steveommen will kick off Day 2 of #HCMSummit8 with a talk on #heartfailure in #obstructiveHCM. We're less than 5 months away & seats are now very limited—register soon to secure your spot: hcmsummit.org/tickets. #hcm #cardiotwitter #hypertrophiccardiomyopathy

Aficamten is a novel cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy. Here come the related building blocks we can provide: buff.ly/46AAwj0 👇 #Chemenu #Aficamten #novel #cardiacmyosininhibitor #hypertrophiccardiomyopathy #obstructiveHCM

#ACC22 🔥Late-Breaking interview on the VALOR-HCM Trial | @DesaiMilindY 🔍Key findings for 👥 with obstructive HCM 💊Effect on clinical practice? 👉Take-home messages 🎥 Watch Now: bit.ly/3Dymj8c #CardioEd #MedEd #Cardiology #ClinicalStudy #ObstructiveHCM

My Commentary on #EXPLORER_HCM trial. Learn more about thenew drug #Mavacamtem dedicated exclusively to #ObstructiveHCM pts without side-effect compared to traditional therapy @SABOURETCardio @ShelleyZieroth @hvanspall @DrNasrien @DrMarthaGulati @AnastasiaSMihai @MicheleSenni

@MyoKardia topline clinical data in hypertrophic cardiomyopathy; plans to start Phase 2 in obstructiveHCM #trvportco bit.ly/MyoPioneer